Findings showed a higher proportion of patients in the etripamil group achieved PSVT conversion to sinus rhythm within 30 minutes compared with those who received placebo. Etripamil was also ...
“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...
With an upcoming PDUFA in the PSVT indication, the company is approaching a binary event that will largely determine its future on the market. Considering Milestone's 2,000 patients worth of drug ...
"We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer ...
"We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided and ...
"We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback